A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age /= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Study of Nivolumab Plus Standard Chemotherapy in Comparison to Brentuximab Vedotin Plus Standard Chemotherapy for Advanced Hodgkin Lymphoma
Sponsor: National Cancer Institute
Enrolling: Male and Female Patients
IRB Number: AAAS8162
U.S. Govt. ID: NCT03907488
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to answer the following question: If we add the study drug nivolumab to standard chemotherapy will it extend your time without disease more than or less than if we add the study drug brentuximab vedotin to standard chemotherapy? We will also compare any side effects you may have and your well-being when you take the study drugs and for up to ten years after you stop taking these drugs to treat the cancer.
This study is closed
Jennifer Amengual, MD
Do You Qualify?
Are you 12 years of age or older? Yes No
Have you been recently diagnosed with advanced stage Hodgkin's Lymphoma? Yes No
Are you willing to undergo extra tests and treatment procedures? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator